Benzinga

Benzinga

Benzinga

martedì, agosto 25

Camp4 Therapeutics Corp

CAMPNASDAQ
Trade with Public
Trade with Public
$4.32
-0.16-3.57%
In chiusura: Aug 21, 5:00 PM EST
$4.40
-0.08-1.79%
Pre-mercato: 4:00 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaRapporto azionario

Camp4 Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Camp4 Therapeutics (CAMP).

Price Target Range — 9 Quarters

Analyst Consensus — 11 Analysts

9Buy
1Hold
1Sell
Consensus RatingOverweight# Analysts11Avg. Consensus PT$8Upside to Avg. PT+86.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026Piper SandlerEdward TenthoffPT RaiseOverweight$12→$15
Jun 16, 2026JP MorganAnupam RamaUpgradeNeutral→Overweight$5→$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.
Benzinga Newsdesk

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.
Avi Kapoor

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top analysts upgraded XOM, CAMP, EXR, WPC, and KRC stocks, with price targets ranging from $44 to $154. See other analysts' views on these stocks.
Avi Kapoor

PRO
JP Morgan Upgrades Camp4 Therapeutics to Overweight, Raises Price Target to $9

JP Morgan analyst Anupam Rama upgrades Camp4 Therapeutics (NASDAQ:CAMP) from Neutral to Overweight and raises the price target from $5 to $9.
Benzinga Newsdesk

PRO
Chardan Capital Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $6.5

Chardan Capital analyst Keay Nakae initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $6.5.
Benzinga Newsdesk

PRO
Rodman & Renshaw Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $7

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $7.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved